Abstract

Aim: The aim of this study is to investigate the relationship between statin use and deep vein thrombosis (DVT).
Material and Methods: Between 2022 and 2024, 1833 patients (926 males; mean age 50.2±0.37 years) who applied to our clinic were included in the study. Following exclusion criteria, the patients were divided into two groups. Group A (n=226): patients diagnosed with DVT, and Group B (n=1607): Patients without DVT. Then, patients diagnosed with DVT (n=226) were divided into two separate subgroups. Group C (n=16): Statin users, and Group D (n=210): statin non-users. Comparisons were made between these groups in terms of demographic data, comorbidities, statin usage, laboratory parameters, and DVT localizations.
Results: Statin usage was significantly lower in the DVT group than in the non-DVT group (16 (7.1%) and 184 (11.4%), respectively, p=0.04). In Group C, the incidence of DVT in the superficial femoral vein was higher than in Group D (p=0.03). Although no statistically significant difference was found, the incidence of DVT in the iliac veins was higher in Group D, while the incidence of DVT in the common femoral vein was higher in Group C. Similarly, rare localizations of DVT are more frequent in Group D than in Group C. DVTs in statin non-users tended to be more widespread than in statin users. A negative significant association was found between statin usage and DVT (p=0.001, OR= -0.084 [95% CI, -0.123–0.036].
Conclusion: We determined that statin usage was lower in patients with DVT than in those without DVT. Statin usage may be protective against DVT. Although no statistically significant difference was found, DVTs in statin non-users tended to be more widespread than in statin users. We found that DVTs in statin non-users affected more proximal segments, whereas in statin users, more distal venous segments were affected.

Key words: Statin, deep vein thrombosis, venous thromboembolism, pulmonary embolism, dyslipidemia